Intercept Pharmaceuticals (ICPT) said Friday its experimental liver disease treatment will face a Food and Drug Administration panel in May, leading ICPT stock to tumble. X The FDA’s Gastrointes...
Intercept Pharmaceuticals (ICPT) said Friday its experimental liver disease treatment will face a Food and Drug Administration panel in May, leading ICPT stock to tumble. X The FDA’s Gastrointes...